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Thromholytic therapy for the removal of intravascular patient to patient and may, at times, he too long to produce 
thrombi was introduced when streptokinase was first given a real benefit in terms of salvage of ischemic myocardium. 
to humans 40 years ago, the same year the American The rate of reocclusion lies somewhere between 10% and 
College of Cardiology was founded. Streptokinase was first 20% and appears not to be influenced by concomitant 
administered to patients with acute myocar- 
dial infarction in 1959. Today, thrombolytic 
therapy has been established to offer signifi- 
cant benefits to patients with acute myocardial 
infarction provided they are brought to med- 
ical attention early enough after the onset of 
symptoms. The two major agents, streptoki- 
nase and recombinant tissue-type plasminogen 
activator @t-PA), have been shown to result in 
reperfusion of infarct-related arteries, to sal- 
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vage ischemic myocardium, to improve myocardial perfor- 
mance and to reduce mortality. 
In spite of these impressive gains, this novel therapy has 
shortcomings. The interval from the start of thrombolytic 
treatment to coronary reperfusion varies significantly from 
Present Status of Thrombolytic Therapy 
After 30 years of clinical trials of thrombolysis for acute 
myocardial infarction (I ,2), much accelerated over the last 
decade (3), the beneficial effects of such therapy are now 
firmly established. The majority of patients given recombi- 
nant tissue-type plasminogen activator (rt-PA) will exhibit 
reperfusion of the infarct-related artery. Streptokinase also 
produces reperfusion. particularly when given very early 
after the acute occlusion. Streptokinase and rt-PA have both 
been shown to reduce infarct size, improve myocardial 
performance and reduce at least the immediate and probably 
the late mortality rates in myocardial infarction. However. 
serious problems with thrombolytic therapy in acute myo- 
cardial infarction remain. First, the incidence of reperfusion, 
which was 100% in early dog experiments (4). varies be- 
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heparin anticoagulation. The rate of bleeding 
complications even with the “fibrin-specific” 
rt-PA is higher than anticipated and may 
range from 10% to 30%. As a consequence, 
intensive efforts are being directed at the 
development of improved thrombolytic agents 
and for adjunctive therapy evaluating better 
anticoagulants than heparin and better anti- 
platelet agents than aspirin. 
This review is a status report summarizing 
where we are in thrombolytic therapy in acute myocardial 
infarction, where we need to improve treatment results and 
what is being done mainly at the preclinical level to bring 
about such improvements. 
(J Am Co11 Cardiol1989;14:837-49) 
tween 60% and 80% in patients. Second, the interval be- 
tween the start of treatment and coronary reperfusion can be 
shortened. Third, the incidence of reocclusion after success- 
ful reperfusion is too high. Finally, the incidence of bleeding 
complications with rt-PA is far higher than originally antic- 
ipated and, in fact, is no different from that with the older 
agents, streptokinase and urokinase. 
Because qf these shortcomings, improved therapies are 
being vigorous/y investigated. Two areas are being inten- 
sively explored: the development of better thrombolytic 
agents of higher efficiency and less bleeding liability than 
rt-PA. and the development of adjunctive therapy with 
agents superior to those currently available. In theory, 
This article is part of a series oj‘urticles celebrating the 
40th anni\~ersary of the American College of Cardiology. 
The series attempts to set the stage ,for the future by 
describing current state of the art management of selected 
mujor cardiovascular problems and the basic knowledge 
that rrill provide directions for udvances in diagnosis and 
therapy. 
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adjunctive pharmacotherapy could encompass anticoagu- 
lants, antiplatelet agents, beta-adrenergic blockers, calcium 
channel blockers, vasodilators, antiarrhythmic drugs, free 
radical scavengers and other agents capable of suppressing 
possible reperfusion injury. 
In this review, we have elected to focus on compounds 
that have an impact on the fibrinolytic enzyme system and 
the clotting cascade or platelet function, or both, to provide 
a framework for discussing therapy aimed at enhancing 
thrombolysis and maintaining patency once reperfusion has 
occurred. This does not imply that other pharmacologic 
approaches are of less interest but that, in the stricter sense, 
drugs used as an adjunct to thrombolysis should complement 
that process and preclude clot recurrence. In the following 
discussion, we will summarize clinical data on currently 
available thrombolytic agents, anticoagulants and antiplate- 
let agents and their advantages and limitations. We will 
cover the theoretical reasons why current regimens are 
suboptimal, and summarize data on experimental agents that 
are appealing from a conceptual standpoint. Although sev- 
eral agents and regimens look promising, it should be em- 
phasized that the available data are largely from preclinical 
pharmacology and in only a few instances have these new 
approaches been tested in preliminary clinical experiments. 
What Is the Current Data Base? 
Time to Reperfusion 
Reperfusion rates. The Thrombolysis in Myocardial In- 
farction (TIMI) group (5) demonstrated that when predomi- 
nantly single-chain tissue plasminogen activator was given at 
its currently approved dose of 100 mg over 3 h (60,20 and 20 
mglh, with an initial bolus of 6 mg), reperfusion rates of 24% 
at 30 mitt, 57% at 60 min and 71% at 90 min were obtained. 
When the dose was increased to 150 mg, earlier reperfusion 
was obtained in more patients (42% at 30 min, 68% at 60 min 
and 76% at 90 min). Interestingly, the 90 min value was only 
slightly improved over that obtained with the 100 mg dose. 
Unfortunately, the incidence of intracranial hemorrhage at 
this high dose was subsequently observed in TIMI- (6) to be 
1.6%, more than twice that at the 100 mg dose. This resulted 
in the higher dose being abandoned. The TIMI- trial (7) also 
demonstrated that streptokinase given in the currently ap- 
proved dose of 1.5 million U over 1 h resulted in substan- 
tially lower reperfusion rates compared with rt-PA at 30 min 
(8%), 60 min (23%) and 90 min (31%). However, in TIMI-1, 
the interval between the onset of symptoms and the start of 
treatment averaged 4.7 h. Whereas such delays in therapy do 
not affect reperfusion rates with rt-PA, they profoundly 
reduce the efficacy of streptokinase. Thus, in TIMI-1, the 90 
min reperfusion rate for patients treated with streptokinase 
within 4 h of the onset of symptoms was twice that for 
patients treated at >4 h after symptom onset (7,8). 
It is clear that faster reperfusion of the infarct-related 
artery is beneficial. Both the empiric observation that throm- 
bolytic therapy administered within the 1st h of symptom 
onset has marked survival advantages over later therapy (9) 
and the theoretical concerns that 15% of myocardium at risk 
dies for every 30 min of persistent occlusion (10) strongly 
support the notion that faster reperfusion improves out- 
come. 
Role of antithrombotic and antiplatelet therapy. The pos- 
sibility that adjunctive anticoagulant or antiplatelet therapy 
may effect faster infarct-related artery thrombolysis is con- 
sistent with the hypothesis that coronary thrombolysis is 
accompanied by procoagulant events (that is, that accretion 
of new platelets and fibrin onto the coronary thrombus takes 
place as thrombolysis proceeds). Similarly, the observation 
that coronary thrombolysis is attended by intermittent pa- 
tency in some patients (11) suggests a possible human 
equivalent to cyclic flow variations in animal models (12), 
which is a platelet-dependent phenomenon. 
Unfortunately, current data that address the impact of 
anticoagulation or antiplatelet therapy on time to reperfusion 
are limited and not illuminating. To obtain such data, se- 
quential angiographic data before and during thrombolytic 
and thrombolytic adjunctive therapy are needed and, in 
many quarters, it is now considered unacceptable to impose 
a delay of 60 min to prepare the patient for angiography 
before definitive therapy for acute myocardial infarction is 
provided. 
Noninvasive diagnosis of reperfusion. The most obvious 
solution to this investigative dilemma is to develop noninva- 
sive means of diagnosing reperfusion. Although the com- 
monly used bedside markers of reperfusion have recently 
been shown (13) to be relatively specific, they are not 
sensitive or useful for making pronouncements regarding the 
reperfusion status of individual patients or groups of patients 
(14). The development of noninvasive markers for reperfu- 
sion is particularly important because early cardiac catheter- 
ization and angioplasty appear to offer no significant advan- 
tages over conservative management in patients in whom 
reperfusion has been achieved (15-18). However, without 
the 90 min angiogram, it may be difficult to identify patients 
who are left with an occluded vessel at that time and who 
might be candidates for salvage angioplasty (18-20) or by- 
pass surgery. 
ReperfusionlPatency Rate 
Patency rates. Patency is typically defined as TIM1 grade 
2 or 3 patency of the infarct-related artery on a 90 min 
angiogram. Unless one knows that the vessel was occluded 
before the administration of the thrombolytic agent, the 
patency rate (not the reperfusion rate) is the variable exam- 
ined. With rt-PA, patency rates have ranged from 61% to 
79% (15,17,21-25); with intravenous streptokinase, a 90 min 
patency rate of 55% has been documented (24). Regardless 
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of the intravenous thrombolytic regimen used, the infarct- 
related coronary artery remains occluded in at 220% of 
patients on the 90 min angiogram (although reperfusion rates 
of 85% to 90% have been reported [26,27] with the use of 
intracoronary thrombolytic regimens). The exact reasons for 
this residual of lesions resistant to therapy are not known. 
Postulated mechanisms include bleeding into the atheroma- 
tous plaque with rapid enlargement of the lesion, spasm at 
the site of the plaque with little contribution to occlusion by 
clot and the occurrence of very platelet-rich thrombi. which 
have recently been shown (28) experimentally to be highly 
resistant to lysis by rt-PA. 
Influence of heparin and aspirin. Only very limited data 
focus on the influence of available anticoagulant and anti- 
platelet agents, heparin and aspirin on time to reperfusion 
and patency rates. Available data (23,25) indicate that hep- 
arin plays no role in either the time to reperfusion or the 
initial patency rate associated with rt-PA therapy. The 
recently published Thrombolysis and Angioplasty in Myo- 
cardial Infarction (TAMI-3) study (23) examined the influ- 
ence of heparin on the 90 min patency rate in a randomized 
prospective trial of patients given rt-PA for acute myocardial 
infarction. Patients allocated to heparin treatment received a 
10,000 unit bolus of heparin concurrent with rt-PA adminis- 
tration, and those assigned to the no heparin arm did not 
receive heparin until after a 90 min angiogram was per- 
formed. There was no significant difference in patency rates 
(73% in the no heparin and 79% in the heparin group). 
Similar data are not available for adjunctive aspirin 
therapy. The majority of rt-PA studies include aspirin as a 
matter of routine in treated as well as control patients and, 
thus, it is not possible to ascertain whether aspirin influences 
the time to or rate of reperfusion. The only data suggesting 
that aspirin may favorably affect outcome come from the 
Second International Study of Infarct Survival (ISIS-2), in 
which death was the end point, as discussed later. 
Rrocclusion 
Clinical documentation. Reocclusion of the infarct- 
related artery after successful thrombolysis can be docu- 
mented either angiographically or clinically. In angiographic 
studies. repeat cardiac catheterization is typically performed 
24 h to several days after thrombolytic administration. 
Because of the “time slice” nature of these observations and 
because spontaneous reperfusion is common (>75% of pla- 
cebo-treated patients in the recent European Cooperative 
Study Group trial (29) had a patent index vessel at follow-up 
angiography 10 to 22 days after admission), it is impossible 
to know if a vessel may have at least transiently reoccluded 
and then recanalized. Thus, it is likely that angiographic 
reocclusion rates may underestimate the real incidence of 
this phenomenon. 
Clinically. reocclusion may be manifested by recurrent 
angina and. in particular, by reinfarction in the same myo- 
cardial location as that observed at the initial presentation. 
Clinical reocclusion rates are less than angiographically 
documented reocclusion rates because cases of reocclusion 
are asymptomatic. 
Angiographic reocclusion rates for rt-PA therapy in re- 
cent publications (7,15,23,25) have been in the 5% to 24% 
range. In TIMI-I (30), reocclusion after streptokinase ther- 
apy occurred in 4 (14%) of 29 patients with reperfusion. 
Pooled data from 10 studies (as discussed in [25]) suggest a 
reocclusion rate after intracoronary streptokinase of 17%. 
Reinfarction rates after thromholytic therapy have been 
documented in numerous recent studies. For patients receiv- 
ing rt-PA. this rate has ranged from 2.4% to 13% (7,16- 
18.21-25.29.31-33) and for those receiving streptokinase 
2.8% to 12% (7,9,24,34-38). 
Role of heparin and aspirin. The role of in-hospital hep- 
arinization in the prevention of reocclusion and reinfarction 
is not clear. In the TAMI- trial (23). the use of heparin 
concomitantly with rt-PA as opposed to rt-PA alone as the 
initial therapy resulted in no improvement in reocclusion 
rate, reinfarction rate, emergency coronary bypass surgery 
and recurrent ischemic events during hospitalization. An- 
other study (39) indicated that delaying heparinization for 12 
h after beginning thrombolytic therapy had no adverse effect 
on reinfarction or reocclusion rates. With a 12 h heparin 
delay. however, bleeding complications were significantly 
less common and less severe. Data from the Gruppo Italian0 
per lo Studio della Streptochinasi Nell’Infarto (GISSI) trial 
(9). which examined the effects of streptokinase versus 
placebo on mortality rates, are also of some interest. Con- 
comitant medication in that trial was left to the discretion of 
the investigators, and approximately 80% of patients did not 
receive therapeutic anticoagulation with heparin. Reinfarc- 
tion rates in the GISSI trial were no ditFerent between patient 
groups that did and did not receive heparin therapy. Not 
until the completion of two trials that randomize patients to 
heparin or no heparin for the duration of hospitalization 
(GISSI-2 and ISIS-3) will the role of heparin in adjunctive 
therapy to thrombolysis be determined. 
With respect to the role of aspirin in preventing reocclu- 
sion, only the large ISIS-2 trial (34) provides data of interest. 
In this study. patients receiving streptokinase plus aspirin 
had a substantially lower chance of experiencing reinfarction 
(I .X%1 than that of patients who received streptokinase but 
no aspirin (2.9%). 
Bleeding Complications 
Incidence. The incidence of bleeding complications in 
selected studies (7) comparing rt-PA and streptokinase in 
addition to three prospective trials focusing on rt-PA with or 
without other treatment modalities (angioplasty, urokinase 
or heparin in TAMI-I [151, TAMI- [211 and TAMI- [23], 
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Table 1. Incidence of Bleeding Complications in Reported Studies 
Study 
(reference) Treatment 
No. of 
Patients 
Incidence of Bleeding 
Major Minor 
(%7c) (%‘c) 
Stroke 
(%) 
TIMI-I (7) SKtH 147 15.6 15.6 
rt-PA t H 143 15.4 17.5 
ECSG-I (22) 
ECSG-2 (29) 
SKtHtA 65 7.7 2.3 
rt-PA t H 64 6.3 26.5 
Placebo t H t A 366 2.2 5.2 
rt-PA t H t A 355 10.2 29.3 
TAMI-I (IS) rt-PA* t H (?PCTA) 386 21 24 
TAMI- (21) rt-PAt H t A(tuk) 147 14 20 
TAMI- (23) rt-PA(+H) 175 14 22 
0 
0 
1.5 
0 
0 
1.7 
0.5 
0.7 
1.2 
*High dose = 150 mg. A = aspirin: ECSG = European Cooperative Study Group; H = heparin; PICA = 
percutaneous transluminal coronary angioplasty; SK = streptokinase: TAMI = Thrombosis and Angioplasty in 
Myocardial Infarction trial; TIM1 = Thrombosis in Myocardial Infarction trial; r&PA = recombinant tissue type 
plasminogen activator: UK = urokinase. 
respectively) are enumerated in Table 1. As mentioned, the 
incidence of bleeding complications with the “fibrin- 
specific” rt-PA was surprisingly high. In fact, in all studies 
cited, rt-PA caused bleeding complications at a rate that was 
not statistically different from that caused by streptokinase. 
The incidence of major bleeding for r&PA ranged from 6.3% 
to 21% in the six studies listed in Table 1 and the incidence 
of all bleeding complications, major and minor, ranged from 
30% to 45%. All the studies cited involved invasive proce- 
dures and a large proportion of the bleeding complications 
encountered with either rt-PA or streptokinase occurred at 
arterial and venous puncture sites. Bleeding from puncture 
sites is extremely common for any thrombolytic agent for 
reasons to be discussed elsewhere in this review. 
Role of heparin or aspirin. It is not clear from the reports 
cited (7,15,21-23,29) whether the concomitant administra- 
tion of heparin or aspirin, or both, significantly contributed 
to bleeding complications. The exception is TAMI-3, in 
which no difference in the incidence of major bleeding 
complications was seen between the groups receiving early 
heparin in combination with rt-PA and the group receiving 
t-t-PA alone. 
Mortality 
Although thrombolytic therapy clearly improves survival 
after acute myocardial infarction (9,3 1,34,40), the contribu- 
tion of heparin to this process is unknown. Similarly limited 
data are available for aspirin. In ISIS-2, >17,000 patients 
with acute myocardial infarction were randomized to pla- 
cebo, streptokinase, aspirin and aspirin plus placebo thera- 
pies. The 5 week vascular mortality rate was reduced by 21% 
in those taking aspirin compared with those taking placebo. 
Streptokinase alone reduced the mortality rate by 23% 
relative to placebo, and when aspirin was given with strep- 
tokinase, the mortality rate was reduced by 42% compared 
with placebo. 
In conclusion, available data limit an objective assess- 
ment of anticoagulant and antiplatelet therapy as adjuncts to 
thrombolysis. TAMI- demonstrated that heparin probably 
does not favorably influence the acute patency rate, and 
ISIS-2 documented that aspirin has a significant beneficial 
effect on reinfarction and mortality rates when used alone or 
in conjunction with streptokinase. 
Suggested Approaches Toward Improving 
Results of Therapy in 
Coronary Thromholysis 
Newer thrombolytic and anticoagulant agents. The follow- 
ing approaches toward reducing the time to reperfusion, 
reducing the reocclusion rate and reducing bleeding compli- 
cations are being worked on in many laboratories. First, it 
has been suggested that simply changing the dose schedule 
(that is, giving a high dose of t-t-PA over 90 min followed by 
a lower dose over an additional 4 to 6 h) may result in a 
reduction in reocclusion rates. Second, combination therapy 
(for example, rt-PA and urokinase or rt-PA and another 
novel thrombolytic agent, single-chain urokinase [scu-PA]) 
have been considered. Alternative plasminogen activators 
have also been suggested. One such novel activator is a 
chemically modified streptokinase-plasminogen complex, re- 
ferred to as anisoylated streptokinase-plasminogen activator 
complex (APSAC). This preparation has already undergone 
extensive clinical testing. Many additional plasminogen ac- 
tivators have been produced through recombinant DNA 
(deoxyribonucleic acid) technology and are in various stages 
of preclinical testing. Finally and importantly, many labora- 
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tories are focusing their attention on alternative approaches 
toward adjunctive therapy, improved novel types of anti- 
platelet agents as well as novel anticoagulant agents that will 
be more active than heparin in preventing the growth of 
arterial thrombi. In the following discussion, each of these 
approaches will be reviewed. 
Prolonged r&PA administration for the prevention of reoc- 
elusion. A relatively small recent clinical trial (41) tested the 
concept that a maintenance infusion of rt-PA plus heparin 
would reduce the rate of reocclusion. Sixty-eight patients 
with acute myocardial infarction all received rt-PA at a dose 
of 1 mg/kg body weight for 90 min. Coronary angiography at 
90 min revealed a patent infarct-related coronary artery in 52 
patients (76%). These patients were randomized either to 
treatment by continuous infusion of heparin alone (27 pa- 
tients) or to treatment by heparin and a maintenance infusion 
of t-t-PA at a dosage of 0.8 mg/kg over 4 h (25 patients). The 
approach appeared to work, at least immediately. Heparin 
plus maintenance rt-PA resulted in a zero incidence of 
reocclusion; in contrast, five patients (19%) receiving con- 
tinuous heparin infusion alone exhibited reocclusion imme- 
diately. This difference is significant at the p = 0.05 level; 
however, the late reocclusion rates were identical in two 
patients in each group. Also, the incidence of significant 
bleeding complications was substantially higher in the hep- 
arin plus rt-PA maintenance group at as opposed to that in 
the heparin alone group (49% versus 25%, respectively). 
These results bt!ere different from those obtained in a 
similar study by the European Cooperative Study Group 
(25). In the latter study, 40 mg of rt-PA was given over I h. 
followed by the randomized administration of either heparin 
alone or a maintenance infusion of 5 mgih of rt-PA with 
heparin over 6 h. The overall patency rate at 90 min of 
infusion was 66%. The maintenance rt-PA level in plasma 
was 0.08 &ml, which is about 1/10 of the level obtained by 
0.8 mg/kg of rt-PA over 4 h. The early reocclusion rate (6 to 
24 h) was only 7% and was not different between the groups. 
Thus, the approach of prolonged rt-PA infusion for the 
prevention of reocclusion needs to be refined, and the dose 
of rt-PA administered immediately, as well as a continuing 
infusion dose need to be better established to consistently 
reduce reocclusion rates while avoiding excessive bleeding 
complications. 
New Agents: Some Theoretical Considerations 
A basic understanding of the fibrinolytic enzyme system, 
the consequences of its activation and certain features of the 
coagulation system is necessary to understand the rationale 
for the development of new fibrinolytic agents, new antico- 
agulant drugs and antiplatelet agents. Certain basic concepts 
pertaining to the mechanism of action of older agents as 
opposed to agents under development also need to be 
introduced. 
The fibrinolytic enzyme system. In a recently published 
review (3). we extensively discussed the biochemistry of the 
fibrinolytic enzyme system. From this review, the following 
points need to be reemphasized as pertinent to the present 
discussion. 
I) Plasminogen activators. The physiologic activators are 
rt-PA, single chain urokinase-type plasminogen activator 
(SW-PA) and two chain urokinase (tcu-PA) usually referred 
to as urokinase. a term used in this review. In addition to 
these physiologic plasminogen activators. the bacterial acti- 
vator streptokinase is widely used clinically. Recombinant 
tissue-type plasminogen activator (rt-PA) and scu-PA pref- 
erentially activate the fibrinolytic proenzyme plasminogen 
adsorbed to fibrin; consequently, rt-PA and scu-PA given at 
moderate doses do not activate plasma plasminogen signifi- 
cantly. The older thrombolytic agents streptokinase and 
urokinase. in contrast, activate plasminogen adsorbed onto 
fibrin and circulating plasma plasminogen with equal effi- 
ciency. The activation of plasma plasminogen results in 
temporary hyperplasminemia and a profound multifactorial 
coagulation defect. Although claimed to be fibrin specific, in 
some patients, rt-PA and scu-PA produce a serious coagu- 
lation defect, although less frequently than that observed 
with streptokinase and urokinase treatment. 
With respect to thefibrin spec$city of rt-PA, it should be 
emphasized that this activator is -fibrin specific, but not 
thromhus specific. Recombinant tissue-type plasminogen 
activator does not distinguish between the target thrombus 
and hemostatic plugs consisting of platelets and fibrin occur- 
ring any place in the circulation including arterial and venous 
puncture sites. Therefore, at best, most fibrin-specific agents 
we can produce still possess a serious liability of causing 
bleeding from arterial and venous puncture sites and other 
potential bleeding sites such as stress ulcers and small blood 
vessels in the cerebral circulation. 
2) Plasminogen activator inhibitors, particularly plasmin- 
ogen activator inhibitor 1 IPAI-1) (summarized in [3]). 
Plasminogen activator inhibitor 1 is synthesized in and 
secreted by endothelial cells and megakaryocytes. It is found 
in plasma at varying concentrations, exists in platelets at 
high concentrations and is released during platelet activa- 
tion. Very large quantities of PAI-I have recently been 
demonstrated to be present bound to subendothelial connec- 
tive tissue. Plasminogen activator inhibitors are found at 
increased concentrations in patients with venous throm- 
boembolism, in patients after acute myocardial infarction 
(42) and in patients with conditions predisposing to throm- 
boembolic disease. Plasminogen activator inhibitors rapidly 
and efficiently inhibit rt-PA, urokinase and PAI-I in plasma, 
in platelet-rich fibrin thrombi and in subendothelial connec- 
tive tissue, and may unfavorably change the therapeutic 
outcome of thrombolytic therapy in some patients. 
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Figure 1. Interactions between the contact activation system of 
coagulation, the fibrinolytic enzyme system and the kallikrein-kinin 
system of human plasma. For details, see text. 
Activation of clotting and platelets through activation of the 
fibrinolytic enzyme system. The administration of massive 
quantities of plasminogen activators results in the activation 
of coagulation. The major enzyme systems in plasma (Fig. 
l), the clotting system, the fibrinolytic enzyme system, the 
kallikrein-kinin system and the complement system are 
interdependent systems sharing activators as well as inhibi- 
tors (43). The earliest steps of the intrinsic coagulation 
pathway involve factor XII (Hageman factor) plus two 
proteins from the kallikrein-kinin system, prekallikrein and 
high molecular weight kininogen. Hageman factor on nega- 
tively charged surfaces is activated by plasmin or kallikrein 
(43). Once Hageman factor is activated, the clotting cascade 
is set in motion by means of the intrinsic pathway, with 
activation of factor XI to factor Xla; it causes massive 
activation of prekallikrein to kallikrein, which works on 
kininogens to release kinins. Activated factor XIIa also 
activates clotting factor VII and sets in motion the chain 
reaction resulting in clotting by means of the extrinsic 
pathway. Kallikrein also activates scu-PA to urokinase, 
which in turn results in additional activation of the fibrino- 
lytic enzyme system. Thus, activation of the fibrinolytic 
enzyme system causes activation of clotting and of the 
kallikrein-kinin system, with the potential for hypotensive 
reactions that do, indeed, occur when too much streptoki- 
nase is given too fast. 
interest that in the study by Owen et al. (44), elevations in 
fibrinopeptide A after either &PA or streptokinase adminis- 
tration occurred despite concurrent heparin therapy (5,000 U 
as a bolus, followed by 1,000 U/h). The observation that 
thrombin generation occurs despite heparinization raises the 
possibility that thrombin generation occurs by means of 
pathways not generally recognized in the classic scheme of 
blood coagulation. Although never extensively described, on 
the basis of animal experiments and clinical observations, it 
has been suspected by many that heparin, even though an 
extremely effective anticoagulant on the venous side of the 
circulation, is far less effective on the arterial side. Accord- 
ing to a hypothesis, which is being widely examined and for 
which we have persuasive preliminary evidence (46), alpha- 
thrombin, the final enzyme in the coagulation cascade, 
probably exists as different molecular entities in venous, 
relatively cell-poor thrombi and in arterial, cell-rich thrombi. 
In venous thrombi, alpha-thrombin predominates. It is in 
free solution in plasma and is readily inhibited by heparin in 
consort with the heparin cofactor antithrombin III. In arte- 
rial thrombi, the predominant form of thrombin appears to 
be meizothrombin. Meizothrombin remains attached to cells 
and has thrombin activity that is not inhibited by antithrom- 
bin III or heparin. 
Fibrinopeptide A, heparin and thrombin generation. That 
activation of coagulation occurs during rt-PA and streptoki- 
nase therapy in acute myocardial infarction was recently 
shown unequivocally by Owen et al. (44). They demon- 
strated a five- to sevenfold increase over baseline values of 
fibrinopeptide A, a reliable marker for activation of the 
coagulation system. Eisenberg et al. (45) also measured 
fibrinopeptide A levels in a similar group of patients receiv- 
ing streptokinase. In their study, they found that increasing 
levels of fibrinopeptide A during streptokinase therapy cor- 
related with the occurrence of rethrombosis. It is of great 
Another possibility is that the thrombus itself is the 
source of preformed thrombin. Fibrin is known to bind (47) 
and reversibly inactivate thrombin, and this thrombin can be 
liberated by plasmin digestion of the fibrin clot (48). 
Activation of platelets associated with fibrinolytic therapy. 
It has been known for many years from in vitro experiments 
(49) that activation of the fibrinolytic enzyme system results 
in activation of platelets. Activation of platelets was recently 
confirmed (50) in vivo in patients receiving streptokinase for 
the treatment of acute myocardial infarction. A lo- to 20-fold 
increase in the urinary excretion of 2-3-dinor-thromboxane 
B2 and plasma 1 I-dehydro-thromboxane B2 was noted early 
during therapy. These prostaglandins are metabolites of 
thromboxane A2, and the appearance of thromboxane A2 in 
plasma reflects in vivo platelet activation. The implications 
of these findings are that new accretion of fibrin and platelets 
onto the thrombus can occur once thrombolysis is underway 
and that these events may contribute to reocclusion as well 
as delayed time to reperfusion. 
New Agents and Strategies: Preliminary, 
Preclinical and Clinical Results 
Anisoylated plasminogen-streptokinase activator complex 
(APSAC). Streptokinase itself has neither protease nor es- 
terase activity, but when it interacts with human plasmino- 
gen, a one to one stoichiometric complex is formed and the 
proteolytically active serine of plasmin is exposed; this 
complex activates plasminogen. A special form of streptoki- 
nase-plasminogen activator is prepared from such equimolar 
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complexes of streptokinase and human plasminogen. in 
which the catalytic center of the plasminogen molecule is 
bound to an acyl group (51), resulting in an inactive complex. 
In aqueous solution, the acyl group is hydrolyzed and 
catalytic activity regained. With the p-anisoyl derivative 
(anisoylated plasminogen-streptokinase activator complex 
[APSAC]), the in vivo deacylation half-life is about 90 to 110 
min. Thus, APSAC can be considered a sustained release 
streptokinase activator preparation. 
Anisoylated plasminogen-streptokinase activator com- 
plex has theoretical advantages. The temporary masking of 
the catalytic center of the activator complex does not 
interfere with the capacity of the molecule to bind to fibrin 
because the fibrin binding sites of plasminogen. “the kringle 
domains,” are located in the plasminogen molecule well 
separated from the catalytic site. Thus, relative fibrin spec- 
ificity could be conferred, and has been confirmed in in vitro 
(52) and animal (53) experiments in which APSAC proved to 
be more efficient in lysing experimental thrombi and caused 
less fibrinogen depletion than did streptokinase-plasmin. 
However, at doses sufficient to cause coronary reperfusion 
(30 mg as a bolus injection) in humans, APSAC causes 
considerable fibrinogen depletion and a rate of bleeding 
complications not apparently different from that of streptoki- 
nase (54). Furthermore, hypotensive reactions have occa- 
sionally been reported (55) in patients. Although APSAC has 
been shown to bind less streptokinase-neutralizing antibody 
than streptokinase (56), the incidence of clinical allergic 
anaphylactic reactions is similar to that observed with strep- 
tokinase (57). The prolonged half-life for APSAC (90 to I10 
min) permits bolus administration. The “sustained release” 
characteristics of APSAC also ensure relatively constant 
levels of streptokinase throughout the treatment period. 
Thus, excessive streptokinase levels capable of completely 
depleting plasma plasminogen are not reached. and this may 
explain why reperfusion rates are generally somewhat higher 
with APSAC than with streptokinase (3). 
When instituted early after the onset of symptoms, 
APSAC therapy has led to a reperfusion rate of approxi- 
mately 65% and a patency rate of approximately 75% in 
several clinical studies (summarized in [57]). In the large 
placebo-controlled APSAC Intervention Mortality Study 
(AIMS) (58), APSAC administration in acute myocardial 
infarction resulted in an impressive 47% reduction in mor- 
tality rate. 
XII-PA thrombolytic combinations. Clot-specific throm- 
bolysis by natural or recombinant scu-PA has been demon- 
strated in animal models of venous and coronary artery 
thrombosis (59). In patients with acute myocardial infarc- 
tion, intravenous infusion of 40 to 70 mg over I h resulted in 
coronary artery reperfusion in 75% of patients, but pro- 
nounced fibrinogen depletion in 25% (60). 
Synergistic combinations of rt-PA with XX-PA or with 
urokinase have worked well in animal experiments (61). 
Combinations of rt-PA and scu-PA have also been effica- 
cious in small uncontrolled studies (62,63) in patients with 
acute myocardial infarction. In a larger trial (21) evaluating 
the efficacy of rt-PA-urokinase combined therapy, only high 
doses of the two agents (I mgikg of rt-PA and 2 million U of 
urokinase) achieved patency rates at 90 min comparable to 
those achieved with rt-PA alone (73% versus 75%, respec- 
tively): additionally, the reocclusion rate was not statisti- 
cally different among patients receiving the combination 
therapy than in those receiving rt-PA alone. Thus, the 
combination of two plasminogen activators to date does not 
appear to offer clear advantages over rt-PA alone. 
Mutant plasminogen activators. Soon after the first suc- 
cessful attempt to clone and express human rt-PA (64), work 
in many laboratories was initiated to create rt-PA mutants 
through site-directed mutagenesis in an attempt to create 
molecules of improved functional properties (65). Recombi- 
nant tissue plasminogen activator seems to have evolved 
through “exon shuffling,” and in the rt-PA. protein-specific 
structures or “domains” encoded by specific exons bear 
strong structural homology to similar domains in other 
proteins. Evidence accumulated to date (65) suggests that 
discrete rt-PA domains possess discrete and specific func- 
tional properties. 
The domains in rt-PA from the N-terminus to the C- 
terminus are named: finger, epidermal growth factor, kringle 
1. kringle 3 and serine protease. The finger and kringle 2 
domains have been shown by several laboratories to be 
involved in rt-PA binding to fibrin (summarized in [65]). The 
epidermal growth factor domain may play a role in &PA 
binding to cells. The kringle I domain has not been assigned 
a function with certainty, except that it contains on residue 
Asn,,,. a complex, high mannose, branched carbohydrate 
side chain that is probably responsible for the effective 
binding, internalization and catabolism of rt-PA by normal 
hepatocytes (66). The serine protease domain catalyzes the 
conversion of plasminogen to plasmin. 
Attempts to produce rt-PA mutants aim at improving the 
following less than desirable properties of the enzyme. 1) 
Recombinant tissue plasminogen activator is a less catalyti- 
cally efficient plasminogen activator than is urokinase, even 
when adsorbed to a fibrin clot (67,68). 2) The fibrin speci- 
ficity. although considerable, is limited as evidenced by the 
significant incidence of fibrinogen depletion in patients re- 
ceiving high doses of rt-PA (69). 3) The activity of rt-PA is 
attenuated by several plasma inhibitors, mainly PAI-I (42). 
4) Like all plasminogen activators, rt-PA activates clotting as 
well as platelets. 5) Finally, the biologic half-life of rt-PA is 
very short (~5 min in humans) (70). Therefore, improved 
plasminogen activators should have a higher catalytic effi- 
ciency than has rt-PA, thereby theoretically reducing the 
time to reperfusion. should be more fibrin-specific than rt-PA 
and, therefore, theoretically cause less bleeding, and should 
have a lower affinity for inhibitors to make the molecule 
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more effective than rt-PA. They should not activate clotting 
or platelets and should posses a longer half-life than rt-PA. 
The different strategies involved in creating such mole- 
cules include: 1) deletion of one or several domains (71-77); 
2) removal of one or more carbohydrate chains by point 
mutation or by changing appropriate asparagine residues to 
which N-linked carbohydrate is attached (78); 3) substitution 
of residue Arg,,, (79) thereby blocking the conversion of 
single chain to two chain rt-PA, which normally occurs 
during purification and in vivo; and 4) creation of hybrid or 
chimeric proteins in which part or all of the N-terminal 
portion of rt-PA, which imparts fibrin-specificity to the 
molecule, is hooked up to the urokinase carboxy terminal 
serine protease domain (80-83). In an alternative and prin- 
cipally different approach, the serine protease domains of 
rt-PA or urokinase are conjugated to fibrin-specific mono- 
clonal antibodies either through chemical linkage or protein 
engineering (84,85). To date, most of these attempts have 
met with only limited success. Hybrids of rt-PA-urokinase or 
scu-plasminogen activators have been constructed. These 
molecules usually possess better catalytic efficiency than 
rt-PA, but possess significantly lower fibrin specificity. 
Mutants of higher fibrin specijicity than rt-PA have not 
been successfully produced so far. However, rt-PA or uroki- 
nase-type plasminogen activator fibrin-specific monoclonal 
antibody chimeras have been shown in vitro and in limited 
animal experiments (86) to produce rapid thrombolysis with- 
out significant fibrinogen depletion, Although certain mu- 
tants with decreased affinity for the PAI-I can be con- 
structed, the manipulations involved also result in loss of 
fibrin specificity and instability of the protein (87-89). Mu- 
tant plasminogen activators that do not cause activation of 
clotting and platelets in vivo, as predicted, cannot be con- 
structed because these side effects probably result from 
activation of plasmin, not from the high concentrations of 
plasminogen activators in the circulation. Thus, these ad- 
verse events must be counteracted by appropriate adjunctive 
therapy. In only one area, the creation of mutants with a 
prolonged half-life, have attempts in several laboratories 
(73,90,91) been successful. Mutants that lack Asn, ,, and its 
attached carbohydrate side chain or mutants that lack epi- 
dermal growth factor show varying degrees of prolongation 
of the half-life up to IO-fold of natural rt-PA in experimental 
animals (92). Preclinical pharmacologic data from rt-PA 
mutants with a prolonged half-life strongly suggest that these 
proteins can shorten the time to reperfusion and can sub- 
stantially delay or eliminate reocclusion. 
Whether such mutants will result in therapeutic gains in 
acute myocardial infarction in patients cannot be predicted 
at this time. Only prospective clinical trials can resolve 
whether these interesting proteins significantly increase the 
benefit to risk ratio of thrombolytic therapy in acute myo- 
cardial infarction (that is, whether an increase in efficacy 
may occur without increased bleeding complications). A 
separate issue is whether a plasminogen activator with a 
prolonged half-life in some instances can be detrimental to 
the patient if and when, for example, urgent coronary bypass 
surgery is contemplated. 
Adjunctive Therapy 
Antiplatelet agents: theoretical considerations. Platelets 
are activated in vivo and start adhering to subendothelial 
connective tissue and aggregating to each other through a 
series of complex and only partly interconnected events. 
Many agonists can cause platelet activation and aggregation. 
Among these are thromboxane A,, a prostaglandin synthe- 
sized in the platelet, collagen, thrombin, adenosine diphos- 
phate (ADP), serotonin and epinephrine (reviewed in [93]). 
Each of these has its own receptors on the platelet and each 
causes receptor-linked signal transduction to activate sev- 
eral different pathways, resulting in platelet adhesion and 
aggregation. One can easily block one of the major pathways 
with a pharmacologic agent, but even if one pathway is 
blocked, other pathways may prevail such that it is ex- 
tremely difficult through conventional pharmacologic mono- 
therapy to completely block platelet activation. 
Platelet adhesions and aggregations. A change in thinking 
has come about in recent years, when it became apparent 
that a common final pathway exists. It is now firmly estab- 
lished that platelets adhere to each other and to the vessel 
wall by making use of “sticky proteins” contained in 
plasma, irrespective of the mechanism of platelet activation. 
The structures in the platelet membranes that allow sticky 
proteins to attach themselves are receptorlike glycoprotein 
molecules of the so-called integrin family (94) found on 
numerous cells. The integrins are of major general impor- 
tance in bringing about cell-cell adhesion and promoting 
cell-cell interactions. On the platelet, a glycoprotein called 
Ib attaches the von Willebrand factor protein to the platelet, 
and von Willebrand factor also sticks to subendothelial 
connective tissues, thereby allowing the platelet to adhere at 
the site of endothelial damage. Another integrin on the 
platelet is called glycoprotein IIb/IIIa (GPIIblIIIa). It will 
bind fibrinogen as well as von Willebrand factor, thereby 
assuring the sticking together of two or more platelets, 
resulting in platelet aggregation. 
That platelets are important in the pathogenesis of coro- 
nary thrombi has long been suspected on the basis of two 
simple observations. 1) Like all arterial thrombi, coronary 
thrombi are platelet rich (95) and contain at least 10 to 20 
times more platelets per unit mass than do venous thrombi. 
2) Many coronary thrombi appear to originate at sites of 
ruptured atheromatous plaques, where subendothelial con- 
nective tissue is exposed, allowing for platelet adhesion and 
aggregation (96). 
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Different classes of antiplatelet agents considered as ad- 
junct therapy. As mentioned, the ISIS-2 study (34) estab- 
lished that aspirin, particularly in combination with strep- 
tokinase, reduced reinfarction and mortality rates. Aspirin is 
a cyclooxygenase inhibitor that works during the initial 
stages in the chain reaction, resulting in thromboxane AZ 
synthesis (93). Attempts at synthesizing cyclooxygenase 
inhibitors more efficient than aspirin have proceeded in 
many laboratories for many years, but without noticeable 
success. Thromboxane synthetase inhibitors specifically in- 
hibit the generation of thromboxane AI, one of the major 
agonists in platelet activation, but to date, agents of this 
class have not proved to be effective inhibitors of platelet 
activation in vivo. Many thromboxane A, receptor antago- 
nists have also been synthesized, and are currently being 
tested and look useful particularly in combination with 
serotonin 5-HT2 receptor antagonists. Another class of 
agents includes phosphodiesterase inhibitors, such as dipyr- 
idamole, and adenylase cyclase enhancers. such as stable 
prostacyclin analogs. This class of drugs works through 
increasing intraplatelet levels of cyclic adenosine monophos- 
phate (AMP), which serves to greatly decrease platelet 
activation. 
Fincllly, agents\ that block platelet GPllblllln und thrreb! 
prevent aggwgation independent of the pcrthwq of wti\vr- 
tion oj’thc plrrtelets are being intensively tested. Monoclonal 
antibodies with GPIIbiIIIa specificity are being tested in 
experimental animals and in early clinical trials. In addition, 
fibrinogenomimetic peptides that also prevent the attach- 
ment of fibrinogen to the GPIIb/IIIa receptor are being 
developed and look very promising. The construction of 
these agents is based on the knowledge of the exact amino 
acid sequences in fibrinogen that are involved in binding 
fibrinogen to the GPIIbiIIIa receptors, thereby promoting 
platelet aggregation. Among these agents, the anti-GPIIbi 
IIIa monoclonal antibodies, the fibrinogenomimetic peptides 
and thromboxane .4, receptor antagonists in combination 
with 5-HT2 antagonists look the most promising and will be 
discussed in the next section. 
Anti-GPIIb/IIIa monoclonal antibodies. In a series of dog 
experiments (97), rt-PA was given by repeated bolus injec- 
tion (0.45 mgikg every 15 min) and the GPIIb/IIIa monoclo- 
nal antibody was given as a single bolus injection in doses 
ranging from 0.1 to 0.8 mg/kg. The time to reperfusion in the 
rt-PA-treated control dogs was 33 min. the incidence of 
reocclusion 100% and the time to reocclusion 1 I min. When 
rt-PA was given in combination with the monoclonal anti- 
body in doses of 0.8, 0.6 and 0.4 mg/kg, striking improve- 
ments in treatment results were observed. The time to 
reperfusion was shortened from 33 min to 6, 8 and 9 min, 
respectively. Reocclusion occurred in none of six dogs 
receiving 0.8 mg, one of five receiving 0.6 mg and three of 
three receiving the 0.4 mg dose of the monoclonal antibody. 
Doses of the monoclonal antibody ~0.4 mgikg resulted in no 
differences from the rt-PA control study. It should be noted, 
however, that the bleeding time in dogs receiving the high 
doses of the monoclonal antibody was excessively pro- 
longed. indicating platelet dysfunction and increased bleed- 
ing risk. 
Fibrinogenomimetic peptides. These analogs of the Arg- 
Gly-Asp-Ser or the gamma-chain carboxy-terminal peptide 
sequences of fibrinogen have been shown (98) to be highly 
effective in the prevention of mesenteric artery thrombosis. 
They are being tested in experimental coronary artery 
thrombosis with or without rt-PA, but results are not yet 
known. The peptides do cause prolongation of the bleeding 
time in animals, but not as marked as that caused by 
GPIIbiIIIa monoclonal antibodies. 
Thromboxane A2 receptor antagonists (in combination with 
5HT2 antagonists). Reports from several laboratories have 
suggested that thromboxane AZ receptor antagonists admin- 
istered as monotherapy as well as serotonin 5-HT, antago- 
nists also administered as single agents are effective in 
preventing or delaying arterial thrombosis. Combination 
therapy using these two classes of agents was recently 
reported (99) to be highly effective as adjunctive therapy in 
dogs after reperfusion with rt-PA. In this study, the inci- 
dence of cyclic flow variations and the time to reocclusion 
were recorded. In control dogs that received heparin after 
successful reperfusion with rt-PA, the time to reocclusion 
was 25 min and all dogs showed cyclic flow variations. In 
dogs receiving a thromboxane A, receptor antagonist 
(SQ29548). the time to reocclusion was prolonged to 86 min. 
but three of five dogs showed cyclic flow patterns. Dogs 
receiving only ketanserin, a S-HT2 antagonist, demonstrated 
a time to reocclusion of 21 min and all demonstrated cyclic 
flow variations. A group of dogs receiving an experimental 
5-HT, antagonist (LY53857) demonstrated a significantly 
prolonged time to reocclusion, but three of four dogs showed 
cyclic flow variations. However, when serotonin and a 
thromboxane antagonist were given together, reocclusion 
was prevented, the time to reocclusion being longer than the 
duration of the experiment (180 min), and in none of 11 dogs 
was the cyclic flow variation pattern observed. Whether 
bleeding occurred with these regimens was not reported. 
Novel anticoagulants. Two types of agents must be con- 
sidered. 
Pure thrombin inhibitors. The first type are pure thrombin 
inhibitors, in contrast to heparin, which in consort with 
antithrombin III inhibits not only thrombin, but practically 
every other serine protease in the coagulation cascade. The 
most potent specific thrombin inhibitor is hirudin, originally 
purified from the medicinal leech Hirudo medicinalis (100) 
and subsequently cloned and expressed in large quantities 
through recombinant DNA technology (101). There are also 
several completely synthetic pure antithrombins; however, 
limited information about these agents is available. Claims 
have been made. mostly in abstract form (102,103), that they 
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are effective in preventing arterial thrombosis, but there is 
also an indication that some of these agents are associated 
with bleeding problems in experimental animals. 
Activated protein C. The second type of agent to be 
considered is activated protein C, an agent that we have had 
experience with since protein C was cloned and expressed in 
the Lilly Research Laboratories (104). Some of its preclinical 
pharmacology was also studied here (105). Activated protein 
C is a natural anticoagulant of major physiologic importance. 
Its mechanism of action is quite elegant in that it displays 
anticoagulant activity only if, when and where thrombin is 
being generated (106); it appears to be quite thrombus 
specific. It has been shown to be effective in the prevention 
of extension of preformed venous thrombi and also is 
extremely effective in the treatment of septic shock with 
disseminated intravascular coagulation. Activated protein C 
has also been found to be effective in the prevention of 
arterial thrombi, where it very surprisingly inhibits platelet 
accumulation as well as fibrin accretion. The major draw- 
back of activated protein C is its relatively short biologic 
half-life of 12 to 20 min, which could make it expensive in 
clinical use. 
Gruber et al. (107) recently reported results obtained with 
activated protein C in a baboon arterial thrombosis model. 
The deposition of platelets in an arterial shunt was quantified 
by computer-assisted gamma camera imaging in six control 
animals and in animals receiving two different doses of 
activated protein C. Platelet deposition was substantially 
reduced in a dose-dependent fashion in thrombi of animals 
receiving activated protein C infusion, and continued effects 
were noted for ~-60 min after the end of the infusion. 
Occlusion of the arterial shunt occurred in all six control 
animals between 25 to 50 min, whereas the arteries remained 
patent in all animals receiving activated protein C for the 2 h 
duration of the experiment. Bleeding times remained normal 
in all animals treated with activated protein C and no clinical 
bleeding was observed. In fact, in all experimental animal 
studies concluded to date, infusions of activated protein C 
have been associated with little, if any, bleeding liability. 
The reasons why activated protein C, which in theory should 
be a pure anticoagulant, inhibits both platelet function and 
thrombus formation without increasing bleeding risk are 
unknown, but they are being intensively investigated at this 
time. 
Conclusions 
The results obtained with thrombolytic therapy in acute 
myocardial infarction to date have been impressive. Never- 
theless, many people have been working to further improve 
results through different strategies, construction of more 
efficient fibrinolytic enzyme preparations and the develop- 
ment of new and improved adjunctive therapies. The mate- 
rial included in this review strongly suggests that it is 
possible to design strategies that could shorten the time to 
reperfusion and perhaps increase the incidence of reperfu- 
sion and decrease the incidence of reocclusion, but it is 
uncertain whether the incidence of bleeding complications 
can be reduced. Indeed, it is possible that some of these 
strategies will result in increased bleeding liability. A possi- 
ble exception is activated protein C, which appears to be 
therapeutically effective at a dose that does not cause 
bleeding. What is certain is that many of these strategies and 
new agents will be tested clinically within the next few years. 
Our review at this time serves notice that the final chapter in 
the saga of thrombolytic therapy in acute myocardial infarc- 
tion is yet to be written. 
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